Basil Systems Raises $11.5 Million to Help Life Sciences Companies Make Smarter, Faster Decisions with AI-Driven Intelligence

Basil Systems 获得 1150 万美元融资，帮助生命科学公司通过人工智能驱动的智能做出更明智、更快的决策。

• With 600M+ indexed records and customers like Johnson & Johnson, Medtronic and Baxter, Basil helps pharma and medtech companies make faster, smarter decisions across product and regulatory lifecycles

• 凭借超过6亿条索引记录和像强生、美敦力以及百特这样的客户，Basil帮助制药和医疗技术公司在产品和监管生命周期中做出更快、更明智的决策。

• Basil Systems transforms fragmented regulatory, post-market and clinical data into real-time, decision-ready insight

• Basil Systems 将分散的监管、上市后和临床数据转化为实时、决策就绪的洞察

BOSTON, April 29, 2025-- Basil Systems, the leading AI-powered product lifecycle intelligence platform for the life sciences industry, announced today it has raised a total of $11.5 million in funding led by Golden Ventures, with participation from Hearst Ventures and Argosy Capital, to expand its enterprise BasilIntel SaaS platform, deepen product capabilities, and accelerate the deployment of data-driven insights across the pharma and medical device industry..

波士顿，2025年4月29日——生命科学行业领先的AI驱动产品生命周期智能平台Basil Systems今日宣布，已获得由Golden Ventures领投的1,150万美元融资，Hearst Ventures和Argosy Capital参与跟投。这笔资金将用于扩展其企业级BasilIntel SaaS平台、深化产品功能，并加速在制药和医疗器械行业中部署数据驱动的洞察。

The new funding will enable Basil to expand its data coverage, onboard additional enterprise clients, and expand the rollout of AI and machine learning to automate high-stakes, high-complexity workflows. The company plans to broaden its support to adjacent players across the life sciences ecosystem, including drug and device manufacturers, suppliers, clinical research organizations, and regulatory agencies..

新资金将使Basil能够扩大其数据覆盖范围，吸纳更多企业客户，并推广人工智能和机器学习的使用，以自动化高风险、高复杂性的工作流程。公司计划加强对生命科学领域相关参与者的支持，包括药品和设备制造商、供应商、临床研究组织以及监管机构。

Life sciences companies face complex, mission-critical operations that are still burdened by manual workflows, siloed data, and outdated tools. From regulatory submissions and clinical planning to post-market surveillance and competitive analysis, critical decisions are often made without clear, timely insight.

生命科学公司面临着复杂且至关重要的运营，这些运营仍然受到手动工作流程、数据孤岛和过时工具的拖累。从监管提交、临床规划到上市后监测和竞争分析，关键决策往往是在缺乏清晰、及时洞察的情况下做出的。

Basil Systems changes that by delivering real-time, AI-powered intelligence that helps teams move faster, collaborate, reduce risk, and make smarter decisions across product development, regulatory strategy, and market execution..

Basil Systems 通过提供实时的、由人工智能驱动的智能解决方案，帮助团队加快速度、促进协作、降低风险，并在产品开发、监管策略和市场执行方面做出更明智的决策。

Basil has built the largest indexed dataset in life sciences, BasilLink, with over 600 million records continuously updated, structured, and growing. This includes regulatory submissions, global drug labels, clinical trials, adverse event reports, guidances, regulations, recalls, citations, inspections, and more..

Basil建立了生命科学领域最大的索引数据集BasilLink，包含超过6亿条记录，持续更新、结构化且不断增长。涵盖监管提交、全球药品标签、临床试验、不良事件报告、指南、法规、召回、引用、检查等更多信息。

Its proprietary platform delivers answers to complex questions in seconds, such as identifying which materials are most often linked to knee implant failures or comparing label changes across oncology therapies in specific patient populations. These insights are accessible through a full-text natural language interface, with API connectivity and enterprise-grade infrastructure designed to support millions of concurrent users..

其专有平台可在数秒内回答复杂问题，例如识别哪些材料最常与膝关节植入失败相关，或比较特定患者群体中肿瘤治疗药物的标签变化。这些洞察可通过全文本自然语言界面获取，并通过API连接和企业级基础设施提供支持，能够承载数百万并发用户。

“Basil Systems is transforming how life sciences companies access and act on regulatory intelligence,” said Bert Amato, Venture Partner, Golden Ventures and Board Director. “What once took teams weeks or months of manual effort using disconnected systems, Basil now delivers in real time by providing actionable insights that drive better product decisions, mitigate risk, and accelerate approvals.

“Basil Systems 正在改变生命科学公司获取和利用监管情报的方式，”Golden Ventures 风险合伙人兼董事会董事 Bert Amato 表示。“过去，团队需要花费数周或数月的时间手动操作分散的系统，而如今 Basil 能够通过提供可操作的洞察实时完成这些工作，从而推动更明智的产品决策、降低风险并加速审批进程。

This isn’t just a workflow improvement, it’s a fundamental shift in how healthcare innovation gets to market.”.

这不仅仅是工作流程的改进，更是医疗创新走向市场方式的根本转变。

“Basil Systems has built the most comprehensive, structured dataset in life sciences, with over 600 million records spanning regulatory filings, clinical trials, post-market events, drug labels, and more,” said Anthony Cirurgiao, CEO and Founder, Basil Systems. “Our AI-powered platform transforms that data into real-time answers for the strategic questions that drive product success.

“Basil Systems 构建了生命科学领域最全面、最结构化的数据集，包含超过6亿条记录，涵盖监管文件、临床试验、上市后事件、药品标签等，”Basil Systems首席执行官兼创始人安东尼·奇鲁吉奥表示，“我们的人工智能平台将这些数据转化为实时答案，解答推动产品成功的关键战略问题。”

We’re not just accelerating workflows and decision making, but creating a new standard for how life sciences companies make critical decisions across innovation, regulatory, safety and commercialization.”.

“我们不仅仅是在加速工作流程和决策，而是在创新、监管、安全和商业化方面为生命科学公司制定一个全新的关键决策标准。”

The BasilIntel platform is already used by four of the five largest global medical device companies and is in active trials with three of the top global pharmaceutical firms.

BasilIntel 平台已经被全球五大医疗器械公司中的四家使用，并且正在与全球三大制药公司中的三家进行积极试验。

Life sciences companies often struggle with fragmented, siloed data spread across departments and formats, which slows down critical regulatory and product decisions. While many solutions promise to fix this, they’re often too complex or unreliable. Basil Systems takes a streamlined, proven approach by using proprietary machine learning algorithms to automatically ingest and unify scattered data into a single, fully indexed source of truth.

生命科学公司常常面临分散在各部门和格式之间的碎片化、孤立数据的困扰，这减缓了关键的监管和产品决策。尽管许多解决方案声称能够解决这一问题，但它们往往过于复杂或不可靠。Basil Systems 采用了一种简化且经过验证的方法，利用专有的机器学习算法自动收集并统一分散的数据，将其整合为单一的、完全索引的真实数据源。

The result is faster access to insights, leaner operations, and a scalable foundation for AI-driven decision-making across the enterprise..

结果是更快地获取洞察、更精简的运营，以及为企业范围内 AI 驱动决策提供的可扩展基础。

“Basil has built a centralized intelligence engine for how medical products are developed, approved, and perform in-market,” said Mohamed Shariff, Director Regulatory Affairs, J&J. “With unmatched depth in regulatory and real-world life sciences data, Basil gives companies the visibility and analytics they need to make faster, smarter decisions.

“Basil建立了一个集中式智能引擎，用于医疗产品的开发、审批及市场表现，”强生公司监管事务总监穆罕默德·沙里夫表示。“凭借在监管和真实世界生命科学数据方面的无与伦比的深度，Basil为公司提供了所需的可见性和分析能力，以帮助它们更快、更明智地做出决策。”

It’s becoming the default infrastructure layer for data-driven strategy in life sciences.”.

“它正在成为生命科学领域数据驱动战略的默认基础设施层。”

In addition to core regulatory and clinical insights, Basil’s platform is used for strategic product development, supply chain optimization, risk mitigation, and real-world evidence (RWE) analysis. It supports use cases across regulatory, clinical, quality, medical affairs, and commercial divisions to provide a unified system of record and intelligence..

除了核心的监管和临床洞察，Basil的平台还用于战略产品开发、供应链优化、风险缓解以及真实世界证据（RWE）分析。它支持跨越监管、临床、质量、医学事务和商业部门的用例，以提供一个统一的记录和情报系统。

About Basil Systems

关于Basil Systems

Basil Systems delivers an AI-powered SaaS platform transforming how pharma and MedTech companies manage regulatory, clinical, and product lifecycle strategy. By structuring the world’s largest indexed database of regulatory, drug, device, and post-market data, Basil helps life sciences organizations accelerate development, reduce risk, and improve product performance.

Basil Systems 提供了一个由人工智能驱动的 SaaS 平台，革新了制药和医疗技术公司管理法规、临床和产品生命周期策略的方式。通过构建全球最大的法规、药物、设备和上市后数据索引数据库，Basil 帮助生命科学组织加速开发、降低风险并提升产品性能。

Trusted by industry leaders, Basil turns complex data into actionable insights that drive better decisions and better patient outcomes. Learn more at www.basilsystems.com and follow us on LinkedIn..

受到行业领导者的信赖，Basil将复杂的数据转化为可操作的见解，推动更好的决策和更好的患者结果。更多信息请访问www.basilsystems.com，并在LinkedIn上关注我们。

Contact:

联系：

Media Contact

媒体联系人

Kimberly Ha

金伯利·哈

KKH Advisors

KKH顾问公司

917-291-5744

917-291-5744

kimberly.ha@kkhadvisors.com

kimberly.ha@kkhadvisors.com